Nordea Investment Management AB Raises Stock Holdings in Hologic, Inc. $HOLX

Nordea Investment Management AB increased its position in Hologic, Inc. (NASDAQ:HOLX) by 7.2% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,587,414 shares of the medical equipment provider’s stock after purchasing an additional 174,828 shares during the period. Nordea Investment Management AB’s holdings in Hologic were worth $168,674,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in HOLX. Victory Capital Management Inc. increased its position in Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the period. Allspring Global Investments Holdings LLC increased its position in Hologic by 473.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock valued at $111,180,000 after purchasing an additional 1,405,085 shares during the period. Nuance Investments LLC increased its position in Hologic by 623.7% during the 1st quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after purchasing an additional 931,920 shares during the period. Invesco Ltd. increased its position in Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after purchasing an additional 764,573 shares during the period. Finally, Nuveen LLC purchased a new position in Hologic during the 1st quarter valued at $30,317,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of research analyst reports. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. UBS Group upped their target price on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Wall Street Zen downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Finally, Argus upped their target price on shares of Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.15.

Hologic Stock Up 2.0%

NASDAQ:HOLX opened at $69.85 on Friday. The firm’s 50-day moving average price is $67.11 and its 200-day moving average price is $63.51. The company has a market capitalization of $15.54 billion, a PE ratio of 28.98, a P/E/G ratio of 2.35 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm posted $1.06 EPS. Hologic’s revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.